University of North Carolina, Chapel Hill

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).

1,109 total trials 108 currently recruiting 881 completed early-phase tilt top decile by trial count

University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.

University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.

Top-decile sponsor footprint

University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,109 total, page 18 of 23

COMPLETED

The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure

NCT01971944

COMPLETED NA

Testing the Efficacy of an Online Social Network Intervention to Increase Social Support for Physical Activity

NCT01421758

COMPLETED Phase 1

Human Cytochrome P450 4F Enzymes and Drug Interactions

NCT01250535

COMPLETED NA

Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2

NCT01244568

TERMINATED Phase 1

Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults

NCT01274429

TERMINATED NA

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

NCT01241942

COMPLETED Phase 1

Curcumin Biomarkers

NCT01333917

COMPLETED Phase 2

Perimenopausal Estrogen Replacement Therapy Study

NCT01308814

COMPLETED NA

Tick-borne Illness and Clothing Study

NCT01454414

COMPLETED NA

PRESENCE 2: Predicting Sedentary Entertainment Choices and Effects

NCT01523795

COMPLETED

Omega-6 to Omega-3 Fatty Acid Ratio and Higher Order Cognitive Function in 7-to 9-year-olds

NCT01823419

COMPLETED NA

Depression Treatment for Low Income Substance Users

NCT01189552

COMPLETED NA

Discharge Planning for Elderly Patients in the Emergency Department: Use of a Brief Phone Call After Discharge to Improve Medication Utilization and Physician Follow-up

NCT01207180

COMPLETED NA

Technology-Enhanced Helping the Noncompliant Child

NCT01367847

COMPLETED

Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics

NCT01663298

COMPLETED

Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults

NCT01203332

COMPLETED Phase 1

Oxytocin Treatment of Alcohol Withdrawal

NCT01212185

COMPLETED NA

Treatment for Depression Among HIV-Infected Youth

NCT01049789

COMPLETED Phase 1

Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn

NCT01149395

COMPLETED Phase 1

Pounds Off Digitally (POD): The Use of Podcasting and Mobile Media to Promote Weight Loss

NCT01139255

COMPLETED NA

Effects of 2 Different Broccoli Sprout Containing Supplements on Nasal Cells in Healthy Volunteers

NCT01129466

COMPLETED

Female Upper Genital Tract in HIV-infected Women

NCT02160392

COMPLETED

CDC-ATN Linkage Evaluation

NCT02366533

COMPLETED

Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate

NCT00770887

COMPLETED Phase 1

Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract

NCT01331486

COMPLETED

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

NCT01180075

COMPLETED Phase 1

Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling

NCT01217359

COMPLETED

ID & Testing in Male Partners

NCT01033812

COMPLETED NA

Endothelial Cell Loss and Induced Astigmatism After Wound-directed and Wound-assisted IOL Injection

NCT01250964

COMPLETED Phase 2

Clopidogrel Pharmacogenomics Project

NCT01097343

COMPLETED Phase 1

Do Acid Sensing Ion Channels Contribute to Heartburn?

NCT01095133

COMPLETED NA

A Representational Intervention to Promote Preparation for End-of-life Decision Making

NCT01259011

COMPLETED Phase 2

Development of an Empowerment Intervention for Young Women Living With HIV

NCT01454921

COMPLETED Phase 2

Topical Cyclosporine Suspension for the Treatment of Brittle Nails

NCT01064830

COMPLETED Phase 1

We Can Prevent Diabetes: A Behavioral Intervention to Reduce Diabetes Risk in African Americans

NCT01227473

COMPLETED Phase 2

Computerized HIV/Sexually Transmitted Disease (STD) Prevention Program

NCT00947947

TERMINATED Phase 2

Apremilast in the Treatment of Moderate to Severe Acne

NCT01074502

COMPLETED NA

Preventative Misconception Intervention

NCT01049139

COMPLETED

Fatty Acid Levels and Memory in Breastfed Children

NCT01942434

COMPLETED Phase 2

Sweet Preference and Alcohol Craving

NCT01296646

COMPLETED NA

Efficacy of Retrograde Fill Vs Spontaneous Fill to Assess Voiding Function

NCT01091844

COMPLETED NA

Dissemination of a Weight Management Program Among US Veterans

NCT00998452

TERMINATED Phase 2

Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

NCT01036802

COMPLETED NA

Oxytocin Treatment of Schizophrenia

NCT01028677

COMPLETED Phase 1

Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis

NCT01094704

COMPLETED NA

Impact of Host Iron Status and Iron Supplement Use on Erythrocytic Stage of Plasmodium Falciparum

NCT01027663

COMPLETED Phase 1

Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C

NCT01018615

COMPLETED NA

Cell Phone Reminders Intervention

NCT01049568

COMPLETED NA

Intensive Computerized Brain Training (ICBT) in Youth With Early Onset Psychosis (EOP)

NCT01027962

COMPLETED

Managerial Database II

NCT01009827

← Previous Page 18 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 111
Phase 2 92
Phase 3 13
Phase 4 56

What is open in the University of North Carolina, Chapel Hill pipeline

108 recruiting of 1,109 indexed (10% open); 881 completed (79%).

Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).

Top condition: Obesity (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of North Carolina, Chapel Hill: open-pipeline peers nationwide

Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of North Carolina, Chapel HillUniversity of FloridaWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthChildren's Hospitals and Clinics of MinnesotaCytokineticsSanofiOhio University
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,109 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this University of North Carolina, Chapel Hill page

1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.

  • 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.